U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Lung Non-Small Cell Squamous Carcinoma

MedGen UID:
1764028
•Concept ID:
C5419208
•
Neoplastic Process

Definition

Lung non-small cell squamous carcinoma that is resistant to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Lung Non-Small Cell Squamous Carcinoma

Professional guidelines

PubMed

Research Progress on Mechanism and Management of Adverse Drug Reactions of Anlotinib.
Li S, Wang H
Drug Des Devel Ther 2023;17:3429-3437. Epub 2023 Nov 15 doi: 10.2147/DDDT.S426898. PMID: 38024530Free PMC Article
Afatinib-based combination regimens for the treatment of solid tumors: rationale, emerging strategies and recent progress.
Bennouna J, Moreno Vera SR
Future Oncol 2016 Feb;12(3):355-72. Epub 2015 Nov 25 doi: 10.2217/fon.15.310. PMID: 26603212
Emphasizing on heat shock protein 90's utility in head and neck squamous cell carcinoma treatment.
Routray S, Sunkavalli A, Swain N, Shankar AA
J Cancer Res Ther 2013 Oct-Dec;9(4):583-6. doi: 10.4103/0973-1482.126451. PMID: 24518700

Recent clinical studies

Etiology

Predictive Capability of PD-L1 Protein Expression for Patients With Advanced NSCLC: Any Differences Based on Histology?
Meshulami N, Tavolacci S, de Miguel-Perez D, Rolfo C, Mack PC, Hirsch FR
Clin Lung Cancer 2023 Jul;24(5):401-406. Epub 2023 Apr 25 doi: 10.1016/j.cllc.2023.03.014. PMID: 37208221
Clinical outcomes of EGFR-TKIs in advanced squamous cell lung cancer.
Si JF, Xiang J, Wei JW, Hao Y, Song ZB
Neoplasma 2022 Jul;69(4):976-982. Epub 2022 May 23 doi: 10.4149/neo_2022_220329N348. PMID: 35603955
Analysis of bevacizumab treatments and metastatic sites of lung cancer.
Sato H, Nagashima H, Akiyama M, Ito T, Hashimoto T, Saikawa H, Utsumi Y, Maemondo M
Cancer Treat Res Commun 2021;26:100290. Epub 2020 Dec 26 doi: 10.1016/j.ctarc.2020.100290. PMID: 33373900
A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753).
Waqar SN, Redman MW, Arnold SM, Hirsch FR, Mack PC, Schwartz LH, Gandara DR, Stinchcombe TE, Leighl NB, Ramalingam SS, Tanna SH, Raddin RS, Minichiello K, Bradley JD, Kelly K, Herbst RS, Papadimitrakopoulou VA
Clin Lung Cancer 2021 May;22(3):170-177. Epub 2020 Oct 14 doi: 10.1016/j.cllc.2020.09.013. PMID: 33221175Free PMC Article
Anti PD-1 and PDL-1 Immunotherapy in the Treatment of Advanced Non- Small Cell Lung Cancer (NSCLC): A Review on Toxicity Profile and its Management.
Sgambato A, Casaluce F, Sacco PC, Palazzolo G, Maione P, Rossi A, Ciardiello F, Gridelli C
Curr Drug Saf 2016;11(1):62-8. doi: 10.2174/1574886311207040289. PMID: 26412670

Diagnosis

Single-cell transcriptomics reveal metastatic CLDN4+ cancer cells underlying the recurrence of malignant pleural effusion in patients with advanced non-small-cell lung cancer.
Zhang X, Wang X, Wen Y, Chen S, Zhou C, Wu F
Clin Transl Med 2024 Apr;14(4):e1649. doi: 10.1002/ctm2.1649. PMID: 38629624Free PMC Article
Cell HE staining smears and paired cell paraffin sections in detection of epithelial growth factor receptor gene of pleural fluid specimens.
Hou F, Qi C, Lu Y, Li F, Hao Z
Zhong Nan Da Xue Xue Bao Yi Xue Ban 2022 Jan 28;47(1):35-44. doi: 10.11817/j.issn.1672-7347.2022.210611. PMID: 35545361Free PMC Article
Bullous pemphigoid associated with squamous cell lung carcinoma showing remarkable response to carboplatin-based chemotherapy:  a case report.
Shrestha P, George MK, Baidya S, Rai SK
J Med Case Rep 2022 May 5;16(1):184. doi: 10.1186/s13256-022-03323-9. PMID: 35513831Free PMC Article
BCL6 confers KRAS-mutant non-small-cell lung cancer resistance to BET inhibitors.
Guo J, Liu Y, Lv J, Zou B, Chen Z, Li K, Feng J, Cai Z, Wei L, Liu M, Pang X
J Clin Invest 2021 Jan 4;131(1) doi: 10.1172/JCI133090. PMID: 33393503Free PMC Article
Emphasizing on heat shock protein 90's utility in head and neck squamous cell carcinoma treatment.
Routray S, Sunkavalli A, Swain N, Shankar AA
J Cancer Res Ther 2013 Oct-Dec;9(4):583-6. doi: 10.4103/0973-1482.126451. PMID: 24518700

Therapy

PTEN Loss Confers Resistance to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells.
Exposito F, Redrado M, Houry M, Hastings K, Molero-Abraham M, Lozano T, Solorzano JL, Sanz-Ortega J, Adradas V, Amat R, Redin E, Leon S, Legarra N, Garcia J, Serrano D, Valencia K, Robles-Oteiza C, Foggetti G, Otegui N, Felip E, Lasarte JJ, Paz-Ares L, Zugazagoitia J, Politi K, Montuenga L, Calvo A
Cancer Res 2023 Aug 1;83(15):2513-2526. doi: 10.1158/0008-5472.CAN-22-3023. PMID: 37311042
A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753).
Waqar SN, Redman MW, Arnold SM, Hirsch FR, Mack PC, Schwartz LH, Gandara DR, Stinchcombe TE, Leighl NB, Ramalingam SS, Tanna SH, Raddin RS, Minichiello K, Bradley JD, Kelly K, Herbst RS, Papadimitrakopoulou VA
Clin Lung Cancer 2021 May;22(3):170-177. Epub 2020 Oct 14 doi: 10.1016/j.cllc.2020.09.013. PMID: 33221175Free PMC Article
Precision medicine for human cancers with Notch signaling dysregulation (Review).
Katoh M, Katoh M
Int J Mol Med 2020 Feb;45(2):279-297. Epub 2019 Dec 4 doi: 10.3892/ijmm.2019.4418. PMID: 31894255Free PMC Article
Camrelizumab: First Global Approval.
Markham A, Keam SJ
Drugs 2019 Aug;79(12):1355-1361. doi: 10.1007/s40265-019-01167-0. PMID: 31313098
Immunotherapy for Advanced Lung Cancer.
Asmar R, Rizvi NA
Cancer J 2015 Sep-Oct;21(5):383-91. doi: 10.1097/PPO.0000000000000151. PMID: 26389763

Prognosis

Predictive Capability of PD-L1 Protein Expression for Patients With Advanced NSCLC: Any Differences Based on Histology?
Meshulami N, Tavolacci S, de Miguel-Perez D, Rolfo C, Mack PC, Hirsch FR
Clin Lung Cancer 2023 Jul;24(5):401-406. Epub 2023 Apr 25 doi: 10.1016/j.cllc.2023.03.014. PMID: 37208221
Multicenter phase II trial of nintedanib plus docetaxel in second-line treatment in advanced non-squamous non-small cell lung cancer patients refractory to first-line platin-based chemotherapy (REFRACT GFPC 02-15 study).
Auliac JB, Monnet I, Bizieux A, Greillier L, Geier M, Falchero L, Le Garff G, Lamy R, Guisier F, Ricordel C, Chouaid C, Vergnenegre A; REFRACT GFPC 02-15 investigators
Lung Cancer 2021 Nov;161:122-127. Epub 2021 Sep 20 doi: 10.1016/j.lungcan.2021.09.007. PMID: 34583220
Analysis of bevacizumab treatments and metastatic sites of lung cancer.
Sato H, Nagashima H, Akiyama M, Ito T, Hashimoto T, Saikawa H, Utsumi Y, Maemondo M
Cancer Treat Res Commun 2021;26:100290. Epub 2020 Dec 26 doi: 10.1016/j.ctarc.2020.100290. PMID: 33373900
A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753).
Waqar SN, Redman MW, Arnold SM, Hirsch FR, Mack PC, Schwartz LH, Gandara DR, Stinchcombe TE, Leighl NB, Ramalingam SS, Tanna SH, Raddin RS, Minichiello K, Bradley JD, Kelly K, Herbst RS, Papadimitrakopoulou VA
Clin Lung Cancer 2021 May;22(3):170-177. Epub 2020 Oct 14 doi: 10.1016/j.cllc.2020.09.013. PMID: 33221175Free PMC Article
Immunotherapy for Advanced Lung Cancer.
Asmar R, Rizvi NA
Cancer J 2015 Sep-Oct;21(5):383-91. doi: 10.1097/PPO.0000000000000151. PMID: 26389763

Clinical prediction guides

PTEN Loss Confers Resistance to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells.
Exposito F, Redrado M, Houry M, Hastings K, Molero-Abraham M, Lozano T, Solorzano JL, Sanz-Ortega J, Adradas V, Amat R, Redin E, Leon S, Legarra N, Garcia J, Serrano D, Valencia K, Robles-Oteiza C, Foggetti G, Otegui N, Felip E, Lasarte JJ, Paz-Ares L, Zugazagoitia J, Politi K, Montuenga L, Calvo A
Cancer Res 2023 Aug 1;83(15):2513-2526. doi: 10.1158/0008-5472.CAN-22-3023. PMID: 37311042
A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753).
Waqar SN, Redman MW, Arnold SM, Hirsch FR, Mack PC, Schwartz LH, Gandara DR, Stinchcombe TE, Leighl NB, Ramalingam SS, Tanna SH, Raddin RS, Minichiello K, Bradley JD, Kelly K, Herbst RS, Papadimitrakopoulou VA
Clin Lung Cancer 2021 May;22(3):170-177. Epub 2020 Oct 14 doi: 10.1016/j.cllc.2020.09.013. PMID: 33221175Free PMC Article
Clinical Application of iNKT Cell-mediated Anti-tumor Activity Against Lung Cancer and Head and Neck Cancer.
Takami M, Ihara F, Motohashi S
Front Immunol 2018;9:2021. Epub 2018 Sep 7 doi: 10.3389/fimmu.2018.02021. PMID: 30245690Free PMC Article
EGFR mutations subset in Chinese lung squamous cell carcinoma patients.
Sun Y, Yin X, Wen MM, Zhang J, Wang XJ, Xia JH, Zhang YN, Zhang ZP, Li XF
Mol Med Rep 2018 Jun;17(6):7575-7584. Epub 2018 Apr 5 doi: 10.3892/mmr.2018.8859. PMID: 29620244Free PMC Article
Immunotherapy for Advanced Lung Cancer.
Asmar R, Rizvi NA
Cancer J 2015 Sep-Oct;21(5):383-91. doi: 10.1097/PPO.0000000000000151. PMID: 26389763

Recent systematic reviews

Will targeted therapy hold its promise? An evidence-based review.
Murdoch D, Sager J
Curr Opin Oncol 2008 Jan;20(1):104-11. doi: 10.1097/CCO.0b013e3282f44b12. PMID: 18043264

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...